General
Showing 1569–1584 of 1897 results
-
Article: PP16 Role of interim and end of treatment positron emission tomography for response assessment and prediction of relapse in posttransplant lymphoproliferative disorder
€2.42 Add to cart -
Article: PP17 Targeting of the histone methyltransferases G9a and GLP in multiple myeloma
€2.42 Add to cart -
Article: PP19 NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction Independently of Previous Hematologic Response
€2.42 Add to cart -
Article: PP2.1 Immunomodulatory effects of rapamycin in Graft versus Host Disease
€2.42 Add to cart -
Article: PP2.2 Treatment of essential thrombocythemia in Europe: an observational study of 3649 high-risk patients in EXELS
€2.42 Add to cart -
Article: PP2.3 A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation
€2.42 Add to cart -
Article: PP2.4 Identifying infectious triggering factors even in the presence of known predisposing diseases is mandatory in hemophagocytic lymphohistiocytosis, a review of 35 cases in two Belgian hospitals
€2.42 Add to cart -
Article: PP2.5 Hypercoagulability in adult sickle cell patients as compared to sickle cell trait subjects and a control group
€2.42 Add to cart -
Article: PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium
€2.42 Add to cart -
Article: PP21 The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results from a multicenter study
€2.42 Add to cart -
Article: PP22 Maternal embryonic leucine zipper kinase (MELK) inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
€2.42 Add to cart -
Article: PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy
€2.42 Add to cart -
Article: PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?
€2.42 Add to cart -
Article: PP3.1 Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease
€2.42 Add to cart -
Article: PP3.2 Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice
€2.42 Add to cart -
Article: PP3.3 The ‘EBMT GVHD App’ improves accuracy of graft versus host disease assessment according to NIH criteria compared to standard practice – A proof of concept
€2.42 Add to cart
